IPO Window Cracks Open: Jersey Mike's Leads a Consumer-Brand Wave
Five deals price this week as the sandwich chain anchors a $1 billion offering — but post-debut performance is brutally bifurcated, and the calendar goes dark next week
The IPO window is open — but only halfway. Five offerings are pricing in the final days of July, the busiest weekly slate in months, anchored by sandwich-chain Jersey Mike’s at a roughly $1 billion deal size[1]. Yet the calendar goes completely dark next week, with zero IPOs scheduled[1], and post-debut performance across 2026 listings is so violently dispersed that calling this a reopened market requires some generosity.
The honest read is that the window is cracked, not thrown open. Issuance is recovering from the post-2021 drought, but the recovery is uneven, selective, and still dominated by SPACs at $10 a share. What follows is a look at the deals pricing now, the pipeline building behind them, and what the first-half post-IPO track record says about what kind of market this actually is.
Jersey Mike’s: The Marquee Deal
The headline event is Jersey Mike’s Subs (NYSE: JMKE), pricing July 30 at $23 per share — the midpoint of its $21–$25 range[1]. The offering of 43.5 million shares raises approximately $1 billion, valuing the chain at a roughly $7.3 billion market cap on roughly $742 million in revenue[1].
Blackstone, which took a majority stake in the chain in 2024, is the driving force behind the accelerated timeline — the Wall Street Journal reported on how the private-equity firm put Jersey Mike’s on a “fast track” to this week’s listing[2]. Barron’s framed the deal as wanting to “be a Wall Street hero,” a nod to the restaurant sector’s recent warm reception from investors[2].
What would have to be true for this to work? The bull case is straightforward: Jersey Mike’s is a profitable, growing franchise with systemwide revenue approaching three-quarters of a billion dollars, operating in a category (fast-casual sandwiches) that has demonstrated pricing power and unit economics through multiple cycles. At roughly $7.3 billion market cap against $742 million in revenue, the implied price-to-sales multiple is near 10x — rich for a restaurant operator, but not unprecedented for one with credible unit-growth runway.
What would have to be true for the bears? That same multiple looks demanding when compared to more mature chains trading at 3–5x sales. If comparable-restaurant sales growth decelerates, or if the Blackstone-backed capital structure carries debt that constrains reinvestment, the premium compresses quickly.
Reformation and Apnimed: Testing Sector Breadth
Two smaller but thematically distinct deals are pricing alongside Jersey Mike’s this week, and together they tell us whether institutional appetite extends beyond a single restaurant chain.
Reformation (NYSE: REF) is a sustainable women’s fashion brand pricing 14.1 million shares at $15–$17, targeting a $225 million raise at a roughly $945 million market cap on $533 million in revenue[1]. The company has built a direct-to-consumer brand around sustainability messaging — a thesis that has burned investors before in the DTC fashion space. The revenue base is real ($533 million is not trivial), but the question for a fashion IPO is always margin durability and customer acquisition cost trajectory, not top-line growth alone.
Apnimed (NASDAQ: APMD) is a clinical-stage biotech developing an oral pill for sleep apnea, pricing 10 million shares at $14–$16 for a $150 million raise, targeting a roughly $608 million valuation[1][2]. The Reuters headline noting the $608 million target is notable because sleep apnea is currently dominated by CPAP hardware — a pill-based approach would be a category disruptor if it clears Phase 3[2]. But clinical-stage biotech IPOs are binary bets on trial outcomes, and the 2026 track record for healthcare debuts is mixed at best.
A fifth deal, Ticketplus (NYSE American: TP), is a small international listing pricing 1.9 million shares at $8–$10 for a $16.9 million raise[1]. And a sixth, East West Ave Acquisition Corp. (NASDAQ: EWAV), is a standard $100 million SPAC at $10[1].
GrubMarket: The Pipeline Behind the Pipeline
While this week’s deals are pricing, the next layer of the pipeline is already forming. GrubMarket, a food supply chain and e-commerce platform, confidentially filed for a U.S. IPO on July 28, according to Reuters and Bloomberg[2][3]. The company is targeting a $4.5 billion valuation, and TechTimes reported it carries a mandatory SEC disclosure tied to a prior revenue overstatement settlement — a wrinkle that will demand close scrutiny when the public S-1 surfaces[3].
GrubMarket raised $50 million in a Series H in February 2026 at a $3.5 billion+ valuation, positioning itself as the “largest private food technology company in the United States”[3]. The jump from $3.5 billion to a $4.5 billion IPO target implies either meaningful revenue growth in the interim or a generous banker. The revenue overstatement settlement adds a disclosure complication that could affect pricing.
A confidential filing is not an imminent listing — the public S-1 could be weeks or months away. But it signals that the pipeline is filling behind this week’s slate, and that the food-tech and supply-chain sector may get its own IPO test in the back half of 2026.
The Bifurcation Problem: 2026 Post-IPO Performance
Here is where the balanced view hardens. The 2026 IPO class is not a rising tide. It is a market where a handful of names have delivered extraordinary returns, a larger group has destroyed capital, and the SPAC infrastructure dominates volume without adding signal.
| Ticker | Company | IPO Date | IPO Price | Current | Return |
|---|---|---|---|---|---|
| COAG | Hemab Therapeutics | May 1 | $18.00 | $44.75 | +148.6% |
| PBLS | Parabilis Medicines | Jun 10 | $20.00 | $31.78 | +61.1% |
| DPC | DPC Holdings | Jun 25 | $33.00 | $44.23 | +34.0% |
| SCTX | Scribe Therapeutics | Jul 24 | $15.00 | $18.36 | +22.4% |
| BSP | Bending Spoons | Jul 1 | $29.00 | $32.70 | +14.1% |
| LIME | Neutron (Lime) | Jul 1 | $25.00 | $26.92 | +7.7% |
| CBRS | Cerebras Systems | May 14 | $185.00 | $169.39 | −8.4% |
| SKHY | SK hynix | Jul 10 | $149.00 | $126.79 | −12.6% |
| SPCX | SpaceX | Jun 12 | $135.00 | $112.55 | −16.6% |
| ITG | ITG Inc. | Jul 1 | $16.00 | $11.98 | −24.1% |
| STDN | Standard Nuclear | Jul 16 | $15.00 | $7.33 | −51.1% |
Source: StockAnalysis.com IPO data[2]. Prices as of July 29, 2026.
The pattern is clear. Biotech and pharma names — Hemab (+149%), Parabilis (+61%), Scribe Therapeutics (+22%) — have been the standout winners. These are small-float, catalyst-driven stories where positive trial data or regulatory milestones can re-rate a stock overnight.
At the other extreme, nuclear and energy debut flops (Standard Nuclear at −51%, Deep Fission at −38%, Fervo Energy at −37%) show that capital-intensive, pre-revenue names are being punished. SK hynix’s ADR listing (−12.6%) and SpaceX (−16.6%) — two of the most anticipated deals of the year — are both trading below their IPO prices. Cerebras, the “biggest IPO of 2026,” surged 70% on its first day to $385 but has since fallen to $169, below its $185 IPO price[2].
The historical analogy worth holding in mind is the 2010–2012 period, when the IPO market partially reopened after the financial crisis. Then, as now, the window was intermittent — bursts of activity followed by dead weeks — and performance was wildly company-specific. The base rate for “a reopened IPO market” is not a flood of uniformly well-received deals. It is a trickle where 20% of names generate most of the positive returns and the rest are a coin flip or worse.
What to Watch Next
- Jersey Mike’s first-day print. A first-day pop above $25 (the top of the range) would signal genuine institutional demand for consumer-brand growth stories. A break below $23 (the midpoint pricing) would echo the Cerebras pattern — strong pre-listing hype, weak follow-through.
- Reformation’s reception. A sustainable-fashion DTC brand pricing in a market that has cooled on DTC since 2021. If it prices within range and holds, it broadens the sector aperture. If it prices below range, the DTC window remains effectively closed.
- Apnimed’s clinical catalyst. As a clinical-stage sleep apnea pill developer, its post-IPO trajectory will depend on trial milestones, not quarterly earnings. Watch for any Phase 3 readout timing disclosure in the S-1.
- GrubMarket’s public S-1. The confidential filing means no terms yet. When the public filing drops, the revenue overstatement settlement disclosure will be the first thing institutional investors scrutinize. The gap between the $3.5 billion Series H valuation and the $4.5 billion IPO target is the key negotiation point.
- The August calendar. No IPOs are currently scheduled for next week or beyond[1]. Whether filings accelerate in mid-August for a September pricing window — the traditional back-to-school issuance push — will determine whether this week is a one-off burst or the start of a sustained reopening.
The base rate says intermittent bursts followed by quiet periods. The 2026 data so far confirms that pattern. This week’s slate is the most active of the summer, but the calendar going dark immediately afterward is the more honest signal about where the market actually stands.
This article is for research and educational purposes only and is not investment advice. IPO investing carries significant risk, and post-debut performance data is subject to change.